Use of Whey Permeate for the Treatment of Metabolic Syndrome

Abstract

The invention relates to the use of whey permeate, preferably sweet whey permeate and more preferably hydrolysed or partially-hydrolysed sweet whey permeate for the production of a pharmaceutical composition for prophylaxis or treatment of symptoms of metabolic syndrome, type-2 diabetes and secondary diseases, said composition being provided for a mammal.

1 . Use of whey permeate for producing a pharmaceutical composition for the prophylaxis or treatment of symptoms of metabolic syndrome or type 2 diabetes or of secondary diseases thereof in a mammal.  
   
   
       2 . The use according to  claim 1 , wherein the symptoms are selected from glucose intolerance or insulin resistance.  
   
   
       3 . The use according to  claim 1 , wherein the secondary diseases are selected from arteriosclerosis, coronary insufficiency, arterial occlusive diseases, myocardial infarction, xanthomas, abdominal discomfort, splenohepatomegaly, pancreatitis, retinal lipemia, stroke, or kidney failure.  
   
   
       4 . The use according to any one of  claims 1  to  3 , wherein the whey permeate is sweet whey permeate.  
   
   
       5 . The use according to any one of claims  1 - 4 , wherein the whey permeate is reduced in lactose.  
   
   
       6 . The use according to any one of  claims 1  to  5 , wherein the composition is microencapsulated.  
   
   
       7 . The use according to any one of  claims 1  to  6 , wherein the composition is formed as an oral form of administration.  
   
   
       8 . The use according to any one of  claims 1  to  7 , wherein the oral form of administration is a lozenge, a powder, granules, a syrup or a juice.  
   
   
       9 . The use according to any one of  claims 1  to  8 , wherein the composition further is a food supplement.  
   
   
       10 . The use according to  claim 9 , wherein the foodstuffs are dietary foodstuffs or food supplements.  
   
   
       11 . The use according to any one of  claims 1  to  10 , wherein the composition further comprises pharmaceutically acceptable additives and/or carriers.  
   
   
       12 . The use according to any one of  claims 1  to  11 , wherein the mammal is a human.  
   
   
       13 . The use according to any one of  claims 1  to  12 , wherein the whey permeate is hydrolyzed.  
   
   
       14 . The use according to any one of  claims 1  to  13 , wherein the whey permeate is partially hydrolyzed.